CoChat
Sign Up
Cited by 258

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Genotoxicity of Retroviral Integration In Hematopoietic Cells

Nienhuis, Arthur W., Dunbar, Cynthia E., Sorrentino, Brian P.·2006·Molecular Therapy
DOI 10.1016/j.ymthe.2006.03.001
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2006.03.001

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 133

  1. Mann, 1983, Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus, Cell, 33, 153, 10.1016/0092-8674(83)90344-6 · DOI
  2. Williams, 1984, Introduction of a new genetic material into pluripotent haematopoietic stem cells of the mouse, Nature, 310, 476, 10.1038/310476a0 · DOI · Paper page
  3. Cavazzana-Calvo, 2000, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science, 288, 669, 10.1126/science.288.5466.669 · DOI · Paper page
  4. Hacein-Bey-Abina, 2002, Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy, N. Engl. J. Med., 346, 1185, 10.1056/NEJMoa012616 · DOI
  5. Gaspar, 2004, Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gamma-retroviral vector, Lancet, 364, 2181, 10.1016/S0140-6736(04)17590-9 · DOI
  6. Thrasher, 2005, Failure of SCID-X1 gene therapy in older patients, Blood, 105, 4255, 10.1182/blood-2004-12-4837 · DOI
  7. Aiuti, 2002, Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning, Science, 296, 2410, 10.1126/science.1070104 · DOI · Paper page
  8. Kohn, 1998, T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates, Nat. Med., 4, 775, 10.1038/nm0798-775 · DOI
  9. Malech, 2004, Progress toward effective gene therapy for chronic granulomatous disease, Jpn. J. Infect. Dis., 57, S27
  10. Siler, 2005, Chronic granulomatous disease gene therapy functionally corrects the phenotype of polymorphonuclear leukocytes (PMN), Mol. Ther., 11, S129, 10.1016/j.ymthe.2005.06.335 · DOI
  11. Ott, 2005, Long-term follow-up of patients successfully treated by gene therapy for X-linked chronic granulomatous disease, Blood, 106, 60a
  12. Gaspar, 2005, Somatic gene therapy for ADA-SCID following cessation of PEG-ADA and use of a mild conditioning regime, Mol. Ther., 11, S13, 10.1016/j.ymthe.2005.06.041 · DOI
  13. Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 · DOI · Paper page
  14. Check, 2005, Gene therapy put on hold as third child develops cancer, Nature, 433, 561
  15. Frederickson, 2005, Report from the 2nd stem cell clonality and genotoxicity retreat, Mol. Ther., 12, 379, 10.1016/j.ymthe.2005.07.694 · DOI
  16. Schwarzwaelder, 2005, Myeloid expansion after insertional activation of MDS/EVI1, PRDM16 and SE+BP1 in a successful chronic granulomatous gene therapy trial, Blood, 106, 61a
  17. Cavazzana-Calvo, 2004, The future of gene therapy: balancing the risks and the benefits of clinical trials, Nature, 427, 779, 10.1038/427779a · DOI
  18. Hoag, 2005, Gene therapy rising?, Nature, 435, 530, 10.1038/nj7041-530a · DOI
  19. Hanawa, 2004, Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a Simian Immunodeficiency Virus-based lentiviral vector system, Blood, 103, 4062, 10.1182/blood-2004-01-0045 · DOI
  20. Relander, 2004, Gene transfer to repopulating human CD34+ cells using amphotrophic-, GALV-, or .RD114-pseudotyped HIV-1-based vectors from stable producer cells, Mol. Ther., 11, 452, 10.1016/j.ymthe.2004.10.014 · DOI
  21. Lucas, 2005, Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes, Blood, 106, 51, 10.1182/blood-2004-11-4491 · DOI
  22. Pinkel, 1970, Treatment of childhood acute lymphocytic leukemia, J. Pediatr., 77, 1089, 10.1016/S0022-3476(70)80101-9 · DOI
  23. Pui, 2004, Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital, Blood, 104, 2690, 10.1182/blood-2004-04-1616 · DOI
  24. Relling, 2003, Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment, Blood, 101, 3862, 10.1182/blood-2002-08-2405 · DOI
  25. Relling, 1999, High incidence of secondary brain tumors after radiotherapy and antimetabolites, Lancet, 354, 34, 10.1016/S0140-6736(98)11079-6 · DOI
  26. Blaese, 1995, T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years, Science, 270, 475, 10.1126/science.270.5235.475 · DOI
  27. Muul, 2003, Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial, Blood, 101, 2563, 10.1182/blood-2002-09-2800 · DOI
  28. Malech, 1997, Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease, Proc. Natl. Acad. Sci. U.S.A., 94, 12133, 10.1073/pnas.94.22.12133 · DOI
  29. Kohn, 2003, American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral mediated gene transfer to hematopoietic stem cells, Mol. Ther., 8, 180, 10.1016/S1525-0016(03)00212-0 · DOI
  30. Fischer, 2005, Severe combined immunodeficiency. A model disease for molecular immunology and therapy, Immunol. Rev., 203, 98, 10.1111/j.0105-2896.2005.00223.x · DOI
  31. Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab., 80, 148, 10.1016/j.ymgme.2003.08.016 · DOI
  32. Couzin, 2005, As Gelsinger case ends, gene therapy suffers another blow, Science, 307, 1028, 10.1126/science.307.5712.1028b · DOI
  33. Kohn, 2003, Occurrence of leukaemia following gene therapy of X-linked SCID, Nat. Rev., Cancer, 3, 477, 10.1038/nrc1122 · DOI
  34. Baum, 2003, Review in translational hematology. Side effects of retroviral gene transfer into hematopoietic stem cells, Blood, 101, 2099, 10.1182/blood-2002-07-2314 · DOI
  35. Fehse, 2004, Pois(s)on—It's a question of dose, Gene Ther., 11, 879, 10.1038/sj.gt.3302270 · DOI
  36. Baum, 2004, Chance or necessity? Insertional mutagenesis in gene therapy and its consequences, Mol. Ther., 9, 5, 10.1016/j.ymthe.2003.10.013 · DOI
  37. von Kalle, 2004, Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable, Semin. Hematol., 41, 303, 10.1053/j.seminhematol.2004.07.007 · DOI
  38. Kang, 2004, The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications, Curr. Hematol. Rep., 3, 274
  39. Sadelain, 2004, Insertional oncogenesis in gene therapy: how much of a risk?, Gene Ther., 11, 569, 10.1038/sj.gt.3302243 · DOI
  40. McCormack, 2004, Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency, N. Engl. J. Med., 350, 913, 10.1056/NEJMra032207 · DOI
  41. Rabbitts, 1999, The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development, Cancer Res., 59, 1794s
  42. Royer-Pokora, 1991, TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11), Oncogene, 6, 1887
  43. Larson, 1995, The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice, Oncogene, 11, 853
  44. Neale, 1995, Ectopic expression of rhombotin-2 causes selective expansion of CD4-CD8- lymphocytes in the thymus and T-cell tumors in transgenic mice, Blood, 86, 3060, 10.1182/blood.V86.8.3060.3060 · DOI
  45. Schroder, 2002, HIV-1 integration in the human genome favors active genes and local hotspots, Cell, 110, 521, 10.1016/S0092-8674(02)00864-4 · DOI · Paper page
  46. Hematti, 2004, Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells, PLoS Biol., 2, e423, 10.1371/journal.pbio.0020423 · DOI
  47. Laufs, 2004, Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns, Mol. Ther., 10, 874, 10.1016/j.ymthe.2004.08.001 · DOI
  48. Imren, 2004, High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells, J. Clin. Invest., 114, 953, 10.1172/JCI200421838 · DOI
  49. Kustikova, 2005, Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking, Science, 308, 1171, 10.1126/science.1105063 · DOI · Paper page
  50. DesGroseillers, 1984, Mapping the viral sequences conferring leukemogenicity and disease specificity in Moloney and amphotrophic murine leukemia viruses, J. Virol., 52, 448, 10.1128/JVI.52.2.448-456.1984 · DOI
  51. Li, 1987, Disease specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides, J. Virol., 61, 693, 10.1128/JVI.61.3.693-700.1987 · DOI
  52. Hacein-Bey, 1996, Gamma-c gene transfer into SCID X1 patient's B-cell lines restores normal high-affinity interleukin-2 receptor expression and function, Blood, 87, 3108, 10.1182/blood.V87.8.3108.bloodjournal8783108 · DOI
  53. Riviere, 1995, Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells, Proc. Natl. Acad. Sci. U.S.A., 92, 6733, 10.1073/pnas.92.15.6733 · DOI
  54. Gardie, 1998, Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia, Blood, 9, 1016, 10.1182/blood.V91.3.1016 · DOI
  55. Suzuki, 2002, New genes involved in cancer identified by retroviral tagging, Nat. Genet., 32, 166, 10.1038/ng949 · DOI
  56. Dave, 2004, Gene therapy insertional mutagenesis insights, Science, 303, 333, 10.1126/science.1091667 · DOI
  57. Dunn, 2004, The immunobiology of cancer immunosurveillance and immunoediting, Immunity, 21, 137, 10.1016/j.immuni.2004.07.017 · DOI
  58. Meyerrose, 2003, Immune-deficient mouse models for analysis of human stem cells, Biotechniques, 35, 1262, 10.2144/03356ss06 · DOI
  59. Buckley, 1999, Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency, N. Engl. J. Med., 340, 508, 10.1056/NEJM199902183400703 · DOI
  60. Antoine, 2003, Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99, Lancet, 361, 553, 10.1016/S0140-6736(03)12513-5 · DOI
  61. Lo, 1999, Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach, Blood, 94, 3027, 10.1182/blood.V94.9.3027 · DOI
  62. Soudais, 2000, Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer, Blood, 95, 3071, 10.1182/blood.V95.10.3071 · DOI
  63. Otsu, 2000, Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy, Mol. Ther., 1, 145, 10.1006/mthe.1999.0020 · DOI
  64. Schmidt, 2005, Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial, Blood, 105, 2699, 10.1182/blood-2004-07-2648 · DOI
  65. Adler, 2004, Analysis of clonal contributions to T lymphoid and myeloid lineages during early hematopoiesis following autologous transplantation in the rhesus macaque, Blood, 104, 730a
  66. Hacein-Bey, 2001, Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells, Hum. Gene Ther., 12, 291, 10.1089/10430340150218422 · DOI
  67. Ficara, 2004, IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential, Mol. Ther., 10, 1096, 10.1016/j.ymthe.2004.08.014 · DOI
  68. Kempler, 1993, Characterization of the Moloney murine leukemia virus stem cell-specific repressor binding site, J. Virol., 193, 690, 10.1006/viro.1993.1177 · DOI
  69. Modin, 2000, Alleviation of murine leukemia virus repression in embryonic carcinoma cells by genetically engineered primer binding sites and artificial tRNA primers, J. Virol., 278, 368, 10.1006/viro.2000.0683 · DOI
  70. Shou, 2004, Mouse models for the analysis of genetic risk factors for hematopoietic transformation in XSCID gene therapy, Mol. Ther., 11, S176
  71. Kamijo, 1999, Tumor spectrum in ARF-deficient mice, Cancer Res., 59, 2217
  72. Kiem, 2004, Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia, Mol. Ther., 9, 389, 10.1016/j.ymthe.2003.12.006 · DOI
  73. Li, 2002, Murine leukemia induced by retroviral gene marking, Science, 296, 497, 10.1126/science.1068893 · DOI · Paper page
  74. Bunting, 1998, Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice, Blood, 92, 2269, 10.1182/blood.V92.7.2269 · DOI
  75. Modlich, 2005, Leukemias following retroviral transfer of multidrug resistance 1 (MDR 1) are driven by combinatorial insertional mutagenesis, Blood, 105, 4235, 10.1182/blood-2004-11-4535 · DOI
  76. Seggewiss, 2006, Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque, Blood, 10.1182/blood-2005-10-4108 · DOI
  77. Moreb, 1997, Human A1, a Bc1-2-related gene, is induced in leukemic cells by cytokines as well as differentiating factors, Leukemia, 11, 998, 10.1038/sj.leu.2400719 · DOI
  78. Kelly, 2003, Prolonged multilineage clonal hematopoiesis in a rhesus recipient of CD34+ cells marked with a RD114 pseudotyped oncoretroviral vector, Blood Cells Mol. Dis., 30, 132, 10.1016/S1079-9796(03)00005-6 · DOI
  79. Persons, 2004, Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors, Blood, 103, 796, 10.1182/blood-2003-05-1572 · DOI
  80. Du, 2005, Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells, Blood, 106, 3932, 10.1182/blood-2005-03-1113 · DOI
  81. Emery, 2005, Use of the cHS4 chromatin insulator to reduce oncoretrovirus vector-mediated genotoxicity, Mol. Ther., 11, s150
  82. Calmels, 2005, Recurrent retroviral vector integration at the MDS1-EVI1 locus in non-human primate hematopoietic cells, Blood, 106, 2530, 10.1182/blood-2005-03-1115 · DOI
  83. Buonamici, 2004, EVI1 induces myelodysplastic syndrome in mice, J. Clin. Invest., 114, 713, 10.1172/JCI21716 · DOI
  84. Barjesteh van Waalwjik van Doom-Khosrovani, 2003, High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients, Blood, 101, 837, 10.1182/blood-2002-05-1459 · DOI
  85. Mitani, 2004, Molecular mechanisms of leukemogenesis by AML1/EVI-1, Oncogene, 23, 4263, 10.1038/sj.onc.1207777 · DOI
  86. Bushman, 2005, Genome-wide analysis of retroviral DNA integration, Nat. Rev., Microbiol., 3, 848, 10.1038/nrmicro1263 · DOI
  87. Bor, 1996, Target-sequence preferences of HIV-1 integration complexes in vitro, Virology, 222, 283, 10.1006/viro.1996.0422 · DOI
  88. Brown, 1987, Correct integration of retroviral DNA in vitro, Cell, 3, 347, 10.1016/0092-8674(87)90287-X · DOI
  89. Wu, 2005, Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses, J. Virol., 79, 5211, 10.1128/JVI.79.8.5211-5214.2005 · DOI
  90. Pryciak, 1992, Retroviral integration into minichromosomes in vitro, EMBO J., 11, 291, 10.1002/j.1460-2075.1992.tb05052.x · DOI
  91. Pruss, 1994, Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core, Proc. Natl. Acad. Sci. U.S.A., 91, 5913, 10.1073/pnas.91.13.5913 · DOI · Paper page
  92. Scherdin, 1990, Transcriptionally active genome regions are preferred targets for retrovirus integration, J. Virol., 64, 907, 10.1128/JVI.64.2.907-912.1990 · DOI
  93. Vijava, 1986, Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin, J. Virol., 60, 683, 10.1128/JVI.60.2.683-692.1986 · DOI
  94. Lander, 2001, Initial sequencing and analysis of the human genome, Nature, 409, 860, 10.1038/35057062 · DOI · Paper page
  95. Schmidt, 2002, Polyclonal long-term repopulating stem cell clones in a primate model, Blood, 100, 2737, 10.1182/blood-2002-02-0407 · DOI
  96. Crise, 2005, Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1, J. Virol., 79, 12199, 10.1128/JVI.79.19.12199-12204.2005 · DOI
  97. Mitchell, 2004, Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences, PLoS Biol., 2, E234, 10.1371/journal.pbio.0020234 · DOI
  98. Trobridge, 2002, Gene transfer with foamy virus vectors, Methods Enzymol., 346, 628, 10.1016/S0076-6879(02)46082-X · DOI
  99. Trobridge, 2006, Foamy virus vector integration sites in normal human cells, Proc. Natl. Acad. Sci. U.S.A., 103, 1498, 10.1073/pnas.0510046103 · DOI
  100. De Palma, 2005, Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells, Blood, 105, 2307, 10.1182/blood-2004-03-0798 · DOI
  101. Ryu, 2005, The effect of globin locus control region (LCR) elements of the MSCV-LTR on promoter trapping by integrated lentiviral vector genomes, Mol. Ther., 11, S4
  102. Bushman, 2003, Targeting survival: integration site selection by retroviruses and LTR-retrotransposons, Cell, 115, 135, 10.1016/S0092-8674(03)00760-8 · DOI
  103. Sandmeyer, 2003, Integration by design, Proc. Natl. Acad. Sci. U.S.A., 100, 5586, 10.1073/pnas.1031802100 · DOI
  104. Ciceri, 2002, Suicide-gene-transducer donor T-cells for controlled graft-versus-host disease and graft-versus-tumor, Int. J. Hematol., 76, 305, 10.1007/BF02982688 · DOI
  105. Bonini, 2003, Safety of retroviral gene marking with a truncated NGF receptor, Nat. Med., 9, 367, 10.1038/nm0403-367 · DOI
  106. Recchia, 2006, Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells, Proc. Natl. Acad. Sci. U.S.A., 103, 1457, 10.1073/pnas.0507496103 · DOI
  107. Hargrove, 2004, Assessment of changes in gene expression caused by insertions of a globin lentiviral vector containing globin regulatory elements or a lentiviral vector containing retroviral LTR elements, Blood, 104, 145, 10.1182/blood.V104.11.497.497 · DOI
  108. Zamore, 2005, Ribo-gnome: the big world of small RNAs, Science, 309, 1519, 10.1126/science.1111444 · DOI
  109. Claverie, 2005, Fewer genes, more noncoding RNA, Science, 309, 1529, 10.1126/science.1116800 · DOI
  110. Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  111. Chen, 2004, MicroRNAs modulate hematopoietic lineage differentiation, Science, 303, 83, 10.1126/science.1091903 · DOI · Paper page
  112. Chen, 2005, MicroRNAs as regulators of mammalian hematopoiesis, Semin. Immunol., 17, 155, 10.1016/j.smim.2005.01.001 · DOI
  113. Calin, 2002, Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. U.S.A., 99, 15524, 10.1073/pnas.242606799 · DOI · Paper page
  114. Calin, 2004, MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias, Proc. Natl. Acad. Sci. U.S.A., 101, 11755, 10.1073/pnas.0404432101 · DOI
  115. Calin, 2004, Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers, Proc. Natl. Acad. Sci. U.S.A., 101, 2993, 10.1073/pnas.0307323101 · DOI
  116. Li, 2005, Ex vivo culture of Fancc−/− stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy, Blood, 105, 3465, 10.1182/blood-2004-06-2483 · DOI · Paper page
  117. Woods, 2003, Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis, Blood, 101, 1284, 10.1182/blood-2002-07-2238 · DOI
  118. Zanjani, 2003, Reversible expression of CD34 by adult human bone marrow long-term engrafting hematopoietic stem cells, Exp. Hematol., 31, 406, 10.1016/S0301-472X(03)00051-1 · DOI
  119. Montini, 2005, Testing the oncogenic potential of retroviral and lentiviral vector integration, Mol. Ther., 11, s150
  120. Yu, 1986, Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells, Proc. Natl. Acad. Sci. U.S.A., 83, 3194, 10.1073/pnas.83.10.3194 · DOI
  121. Zufferey, 1998, Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery, J. Virol., 72, 9873, 10.1128/JVI.72.12.9873-9880.1998 · DOI · Paper page
  122. Zaiss, 2002, RNA 3′ read through of oncoretrovirus and lentivirus: implications for vector safety and efficacy, J. Virol., 76, 7209, 10.1128/JVI.76.14.7209-7219.2002 · DOI
  123. West, 2002, Insulators: many functions, many mechanisms, Genes Dev., 16, 271, 10.1101/gad.954702 · DOI
  124. Recillas-Targa, 2002, Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities, Proc. Natl. Acad. Sci. U.S.A., 99, 6883, 10.1073/pnas.102179399 · DOI
  125. Felsenfeld, 2004, Chromatin boundaries and chromatin domains, Cold Spring Harb. Symp. Quant. Biol., 69, 245, 10.1101/sqb.2004.69.245 · DOI
  126. Harrison, 1989, The gypsy retrotransposons of Drosophila melanogaster: mechanisms of mutagenesis and interaction with the suppressor of Hairy-wing locus, Dev. Genet., 10, 239, 10.1002/dvg.1020100313 · DOI
  127. Emery, 2002, Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo, Blood, 100, 2012, 10.1182/blood-2002-01-0219 · DOI
  128. Ramezani, 2003, Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator, Blood, 101, 4717, 10.1182/blood-2002-09-2991 · DOI
  129. Puthenveetil, 2004, Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector, Blood, 104, 3445, 10.1182/blood-2004-04-1427 · DOI
  130. Recillas-Targa, 2004, Prospects and implications of using chromatin insulators in gene therapy and transgenesis, BioEssays, 26, 796, 10.1002/bies.20059 · DOI
  131. Spencer, 2000, Developments in suicide genes for preclinical and clinical applications, Curr. Opin. Mol. Ther., 2, 433
  132. Uckert, 1998, Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo, Hum. Gene Ther., 9, 855, 10.1089/hum.1998.9.6-855 · DOI
  133. Frank, 2004, Tumor cells escape suicide gene therapy by genetic and epigenetic instability, Blood, 104, 3543, 10.1182/blood-2004-03-0852 · DOI

Cited by

See all 258

Metadata

Authors
Nienhuis, A. W., Dunbar, C. E., & Sorrentino, B. P.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2006-06
Volume
13
Issue
6
Pages
1031-1049
ISSN
1525-0016
DOI
10.1016/j.ymthe.2006.03.001
Cited by
258
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review